Review

Comparing New Anticoagulants

Authors: James M. Wooten, PharmD

Abstract

For years, the pharmaceutical industry has been trying to find a safe and effective drug to replace warfarin. Although warfarin is an effective anticoagulant, its pharmacology, adverse effects, and risk profiles dictate that patients taking this medication must be monitored judiciously. The US Food and Drug Administration has approved two drugs for commercial use, dabigatran and rivaroxaban, that will compete directly with warfarin for use in specific indications. Because of direct marketing to patients, physicians are being asked to comment on these new medications. This brief review illustrates the data available for the two new drugs when compared to warfarin for the specified indications. For some patients, these drugs may be highly beneficial and offer an excellent alternative to warfarin. For others, warfarin may still be the preferred drug.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Murray C. What are the differences between the new oral anticoagulants? Drug information group–University of Illinois–Chicago College of Pharmacy. http://dig.pharm.uic.edu/faq/2011/dec/faq2.aspx. Accessed January 17, 2012.
 
2. Galanis T, Thomson L, Palladino MP, et al. New oral anticoagulants. J Thromb Thrombolysis 2011; 31: 310–320.
 
3. Altman R, Vidal HO. Battle of oral anticoagulants in the field of atrial fibrillation scrutinized from a clinical practice (the real world) perspective. Thromb J 2011; 9: 12.
 
4. Eikelboom JW, Weitz J. New oral anticoagulants for thromboprophylaxis in patients having hip or knee arthroplasty. BMJ 2011; 342: 224–227.
 
5. Camden R, Ottis E. New oral anticoagulant options in the treatment of atrial fibrillation. http://www.acponline.org/about_acp/chapters/mo/mohospitalist-oct11.pdf. Published September 2011. Accessed January 19, 2012.
 
6. Davis EM, Packard KA, Knezevich JT, et al. New and emerging anticoagulant therapy for atrial fibrillation and acute coronary syndrome. Pharmacotherapy 2011; 31: 975–1016.
 
7. Wartak SA, Bartholomew JR. Dabigatran: will it change clinical practice? Clev Clin J Med 2011; 78: 657–664.
 
8. A new era in anticoagulation. http://www.healthtrans.com/Clinical/Transitions_v2/Transitions%20Documents/2012-01-January%20Transitions.pdf. Published January 2012. Accessed January 19, 2012.
 
9. Stöllberger C, Finsterer J. Concerns regarding the use of dabigatran for stroke prevention in atrial fibrillation. Pharmaceuticals 2012; 5: 155–168.
 
10. Wittkowsky A. Novel oral anticoagulants and their role in clinical practice. Pharmacotherapy 2011; 31: 1175–1191.
 
11. Institute of Sage Medication Practices. ISMP medication safety alert. http://www.ismp.org/Newsletters/acutecare/showarticle.asp?ID=12. Published January 12, 2012. Accessed March 29, 2012.
12. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139–1151.
13. Lakkireddy D, Reddy YM, Di Biase L, et al. Feasibility and safety of dabigatran versus warfarin for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation. J Am Coll Cardiol 2012; 59: 1168–1174.
14. Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009; 361: 2342–2352.
15. Eriksson BI, Dahl OE, Rosencher N, et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomized, double-blind, non-inferiority trial.Lancet 2007; 370: 949–956.
16. Eriksson BI, Dahl OE, Rosencher N, et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 2007; 5: 2178–2185.
17. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883–891.